SECURITIES AND EXCHANGE COMMISSION

                            WASHINGTON, D. C.  20549

                                  ____________



                                    FORM 8-K



                                 CURRENT REPORT



                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                        DATE OF REPORT: FEBRUARY 15, 2000
                        (Date of earliest event reported)


                          INCYTE PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


               DELAWARE               0-27488          94-3136539
      (State or other jurisdiction  (Commission      (IRS Employer
           of incorporation)        File Number)  Identification No.)


           3174 PORTER DRIVE, PALO ALTO, CALIFORNIA            94304
           (Address of principal executive offices)          (Zip Code)


       Registrant's telephone number, including area code:  (650) 855-0555



Item  5.     Other  Events.
             -------------

     Attached hereto as Exhibit 99.1 and incorporated by reference herein is the
press  release  dated  February  15,  2000  announcing

Item  7.  Financial  Statements  and  Exhibits.
          ------------------------------------

     (c)     Exhibits

99.1     Press  release  dated  February  15, 2000 announcing the issuance of an
additional  $50  million  of  convertible  subordinated  notes  by  the Company.








                                    SIGNATURE


     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  hereunto  duly  authorized.


     Dated:  February  15,  2000


INCYTE  PHARMACEUTICALS,  INC.



By     /s/  John  M.  Vuko
       -------------------
Name:     John  M.  Vuko

Title:     Executive  Vice  President  and
     Chief  Financial  Officer